Background Vesnarinone, a quinolinone derivative, is a recently synthesized positive inotropic agent that has been shown to dramatically improve the survival of patients with heart failure. However, the mechanism of action of vesnarinone remains unknown. Reversible neutropenia complicated with vesnarinone therapy suggests that vesnarinone may modulate the production of cytokines. Because tumor necrosis factor (TNF)-a and other cytokines have been shown to depress myocardial contractility, we investigated the effects of vesnarinone on the production of various cytokines.
Methods and Results
We studied the effects of vesnarinone on cytokine production by lipopolysaccharide (LPS)-stimulated whole blood from seven patients with heart failure and from five healthy volunteers. Heparinized blood was diluted in RPMI and stimulated with LPS. Vesnarinone was added in a range of 1 to 30 ,ug/mL, the blood was incubated for 24 hours, and interleukin (IL)-1a, IL-1,3, IL-6, TNF-a, interferon (IFN)-y, and granulocyte colony-stimulating factor (G-CSF) were measured by an enzyme-linked immunosorbent assay. LPS stimulation induced a more prominent increase in TNF-a A ccording to the recent concept of heart failure, the primary goals in the management of the disease are to improve the quality of life and to prolong life. Recently developed inotropic agents that increase intracellular cAMP by either stimulating fl-adrenergic receptors or inhibiting phosphodiesterase have produced dramatic short-term hemodynamic benefits in patients with advanced heart failure. However, longterm treatment with these agents results in an unfavorable outcome, with an acceleration of the disease process and an adverse effect on survival. In contrast to these agents, vesnarinone, a quinolinone derivative, is a recently synthesized positive inotropic agent that has been shown to improve both the quality of life and the prognosis of heart failure.1'2 In particular, a recent report by Feldman et a13 demonstrated a dramatic improvement in survival during a 6-month study in patients with heart failure. They pointed out that reversible neutropenia was a complication in 2.5% of the patients treated with vesnarinone.3 This complication has also been associated with vesnarinone treatment in in patients with heart failure than in healthy volunteers. Vesnarinone inhibited the production of TNF-a and IFN-y both in healthy volunteers and in patients with heart failure.
IL-la and IL-1,3 were also suppressed in healthy volunteers, but this response was variable, and a significant reduction was not seen in patients with heart failure. Marked inhibition of G-CSF and other cytokines by vesnarinone was observed in one patient who had developed neutropenia as a result of vesnarinone therapy.
Conclusions Although the number of study patients was small and the results are preliminary, these findings provide evidence that vesnarinone plays an important role in the regulation of cytokines and suggest that the reduction of cytokine release may contribute to the beneficial effects of the drug in the treatment of heart failure. Furthermore, the measurement of cytokines may be useful in predicting the occurrence of neutropenia, which has been occasionally reported in patients treated with vesnarinone. (Circulation. 1994;89:955 -958.)
Key Words * vesnarinone * heart failure * cytokines Japan.2 These findings strongly suggest that vesnarinone has an additional effect of modulating the production of the cytokines that play a substantial role in the pathogenesis of heart failure. Although it has been suggested that the mechanism of action of vesnarinone is related to a slight inhibition of phosphodiesterase III, increased inward calcium current, and reduced potassium current, the true mechanism by which the drug reduces mortality has not been clarified. One possible alternative reason for the beneficial effects of vesnarinone is the recent report that this agent might inhibit the production of some cytokines. 4 In this study, we investigated the effects of vesnarinone on cytokine production in blood from patients with heart failure and from healthy volunteers.
Methods
Seven patients with congestive heart failure (four men and three women; age range, 42 to 74 years; mean+SD age, 58±+12 years) were studied. Cause of heart failure was cardiomyopathy in six patients and valvular heart disease in one patient. Three patients were in New York Heart Association (NYHA) class II and four patients were in NYHA class III. Heart rate IL-la Results  Fig 1 demonstrates that the markedly suppressed levels of IL-1a, IL-1,3, TNF-a, and IFN-y release observed at vesnarinone concentrations of 1 to 30 ug/mL were significantly different than the control levels (70 pg/mL for IL-1a, 593 pg/mL for IL-1/3, 234 pg/mL for TNF-a, and 348 pg/mL for IFN-y, median; P<.05). Vesnarinone caused a dose-dependent reduction in TNF-a release. Reduction of IFN-y release was prominent, and 1 ,ug/mL of vesnarinone suppressed IFN-y to below the detectable level of 20 pg/mL. Elevated levels of IL-6 (33 pg/mL) and G-CSF (21 pg/mL) by LPS stimulation were observed in three individuals, and 1 ,ug/mL of vesnarinone suppressed IL-6 and G-CSF to below the detectable levels (20 pg/mL).
Because a profound reduction in the release of various cytokines was evident in the specimens from healthy volunteers containing 10 gg/mL of vesnarinone, speci- mens from patients with heart failure were studied using this dose of vesnarinone. Median values for LPS-stimulated cytokines in patients with heart failure were 99 pg/mL of IL-la, 667 pg/mL of IL-1,3, 523 pg/mL of TNF-a, and 64 pg/mL of IFN-y (Fig 2) . A significant reduction in TNF-a and IFN-y levels was observed on incubation with vesnarinone in patients with heart failure (P<.05). LPS induced an increase of G-CSF in three patients (114 pg/mL), and vesnarinone reduced G-CSF to below the detectable levels in two of these patients.
LPS-stimulated production of IL-la, IL-1,8, TNF-a, and G-CSF tended to be higher in patients with heart failure than in healthy volunteers (IL-la, 97 versus 70 pg/mL; IL-1,i, 667 versus 593 pg/mL; TNF-a, 523 versus 234 pg/mL; and G-CSF, 114 versus 21 pg/mL), and the increase in TNF-a production was significantly more prominent in patients with heart failure (P<.05).
Marked inhibition of G-CSF (from 205 to <20 pg/ mL), IL-la (from 84 to < 10 pg/mL), IL-1,8 (from 1589 to 58 pg/mL), TFN-a (from 593 to 20 pg/mL) and IFN-y (from 291 to <20 pg/mL) was observed in one patient with valvular heart disease who had developed neutropenia as a result of vesnarinone therapy and had recovered by treatment with recombinant G-CSF (Fig 2,  white dots) .
Discussion
In this study, we demonstrated that vesnarinone inhibited the production of TFN-a and IFN-y by LPSstimulated whole blood from patients with heart failure and from healthy volunteers. Although IL-la and IL-1f3
were also suppressed in the healthy volunteers, a significant reduction was not found in patients with heart failure. LPS stimulation induced a more prominent increase in TNF-a in patients with heart failure. These results suggest that a different mechanism of cytokine regulation may exist in heart failure. Cytokine levels were unaffected by vesnarinone treatment or tendedo be high in a patient with dilated cardiomyopathy mth congestive heart failure. Although the importanceDf these changes is unclear, vesnarinone may have difirent regulatory effects on the production of cytokinein some patients with heart failure.
Cytokines are being increasingly recognized as essntial mediators of normal and pathological immune esponses. It is widely accepted that cytokines are involxd in the cascade of events that lead to a wide rangeDf biological responses to exogenous and endogenus pathogens. An elevated concentration of TNF-a hs been reported in patients with chronic heart failure, ad patients with high concentrations of TNF-a have hd cardiac cachexia.6 TNF-a has been reported to deprss myocardial contractility, alter muscle membrane potntial, lower blood pressure, and precipitate pulmonry edema.7 Repeated TNF-a infusion may lead to a prmanent decrease in myocardial contractility and uimately result in dilated cardiomyopathy.8 Recently, ie direct effects of proinflammatory cytokines on the cotractility of mammalian heart were studied.9 TNFa, IL-6, and IL-2 inhibited the contractility of isolatd hamster papillary muscles in a concentration-depndent, reversible manner. The nitric oxide synthase nhibitor NG-monomethyl-L-arginine blocked these neative inotropic effects. L-Arginine reversed the inhibitry effect of NG-monomethyl-L-arginine. These findigs demonstrate that the direct negative inotropic effectf cytokines is largely mediated by myocardial nitric oxie synthase.10 Thus, the regulation of proinflammatry cytokines may provide new therapeutic strategies in ie treatment of cardiac diseases. Although the numberof study patients was small and the results are preliminay, these findings provide evidence that vesnarinone plys an important role in the regulation of cytokines ad suggest that the reduction of cytokine release contib-utes to the beneficial effects of the drug in the treatment of heart failure.
The marked inhibition of G-CSF observed in one patient with heart failure who had developed neutropenia as a result of vesnarinone therapy suggests that vesnarinone caused neutropenia by the suppression of G-CSF. This result suggests that the measurement of cytokines may be useful in predicting the occurrence of neutropenia in patients with heart failure who are treated with vesnarinone.
